Fosfomycin
Broad-spectrum antibioticsNabrivaOral antibiotics
Lefamulin
Intravenous antibioticsNabrivaNew and investigational antibioticsOral antibioticsPleuromutilin antibiotics
Day after UN calls for new antibiotics, FDA delivers a setback for drug from Nabriva of King of Prussiahttps://www.philly.com/business/health/antibiotic-contepo-multi-drug-resistant-nabrivia-king-of-prussia-20190501.html
Antibiotic resistance and the development of new drugsNabriva
FDA Issues Complete Response Letter to Nabriva for Intravenous Fosfomycinhttps://www.contagionlive.com/news/fda-issues-complete-response-letter-to-nabriva-for-intravenous-fosfomycin
Antibiotic resistance and the development of new drugsNabriva
FDA declines to approve Nabriva's antibiotic for urinary tract infections - Reutershttps://www.reuters.com/article/us-nabriva-fda/fda-declines-to-approve-nabrivas-antibiotic-for-urinary-tract-infections-idUSKCN1S7307
Antibiotic resistance and the development of new drugsNabriva
FDA declines to approve Nabriva's antibiotic for urinary tract infections | World | News | The Journal Pioneerhttps://www.journalpioneer.com/news/world/fda-declines-to-approve-nabrivas-antibiotic-for-urinary-tract-infections-307308/
Antibiotic resistance and the development of new drugsNabriva
FDA rejects Nabriva's antibiotic over manufacturing concerns - Pharmaphorumhttps://pharmaphorum.com/news/fda-rejects-nabrivas-antibiotic-over-manufacturing-concerns/
Antibiotic resistance and the development of new drugsNabriva
Manufacturing concerns spike Nabriva’s plans to launch its first antibiotic — for now – Endpoints Newshttps://endpts.com/manufacturing-concerns-muddles-nabrivas-plans-to-market-its-first-antibiotic/
Antibiotic resistance and the development of new drugsNabriva
Nabriva (NASDAQ:NBRV) Shares Tumble After FDA Issues CRL For Antibiotic Candidate | Benzingahttps://www.benzinga.com/general/biotech/19/05/13639580/nabriva-shares-tumble-after-fda-issues-crl-for-antibiotic-candidate
Antibiotic resistance and the development of new drugsNabriva
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacteria Pneumonia (CABP) Nasdaq:NBRVhttps://www.globenewswire.com/news-release/2019/08/19/1903735/0/en/Nabriva-Therapeutics-Receives-U-S-FDA-Approval-of-Xenleta-lefamulin-to-Treat-Community-Acquired-Bacteria-Pneumonia-CABP.html
2019-08 FDA approves use of lefamulin to treat community-acquired pneumoniaLefamulinNabriva
Nabriva receives FDA approval for Xenletahttps://www.in-pharmatechnologist.com/Article/2019/08/22/Nabriva-receives-FDA-approval-for-Xenleta
2019-08 FDA approves use of lefamulin to treat community-acquired pneumoniaNabriva
Nabriva scores its first FDA nod with novel antibiotic Xenleta | FiercePharmahttps://www.fiercepharma.com/marketing/nabriva-scores-fda-nod-for-novel-antibiotic-to-treat-bacterial-pneumonia
2019-08 FDA approves use of lefamulin to treat community-acquired pneumoniaLefamulinNabriva
Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.https://finance.yahoo.com/news/nabriva-xenleta-lefamulin-treatment-community-110000724.html
LefamulinNabriva

Showing topic

Nabriva
Pharmaceutical makers and biopharmaceutical companies

Names and synonyms

  • Nabriva
  • Nabriva Therapeutics